This article is more than 5 years old. Information may no longer be current.
Researchers identify potential new SLE biomarkers
Click Here to Manage Email Alerts
Study findings presented at the European League Against Rheumatism Annual European Congress of Rheumatology showed a new set of potential biomarkers for systemic lupus erythematosus, including cytokines and chemokines, has been identified.
Twenty plasma samples from patients with systemic lupus erythematosus (SLE) and 20 samples from healthy participants matched for age, gender and ethnicity were obtained through three commercial biorepositories. The samples were analyzed with a 30-plex immunoassay directed at pro-inflammatory cytokines and chemokines. Potential biomarkers were analyzed using a comprehensive database, followed by analysis with Spearman correlation, receiving operator characteristic (ROC) and principle component (PC) analysis.
Significantly higher levels of the chemokine interferon-gamma-inducible protein 10 (IP-10) distinguished samples from patients with SLE from healthy samples, according to the researchers. Of 14 potential biomarkers identified with areas under the ROC curve between 0.856 and 0.975, some were well known as tumor necrosis factor-alpha (TNF-a) components, whereas others were more unusual, such as eotaxon-1, according to the researchers. Other markers of interest included thymus- and activation-regulated chemokine (TARC), interleukin (IL)-16, IL-7 and macrophage inflammatory protein-beta (MIP-1b).
PC one described 36% of the data and was effectively used to distinguish between samples from healthy participants and samples from patients with SLE. Four separate clusters were described by PC two, whereas the biomarkers in PC one were grouped with TNF-a. - by Shirley Pulawski
Reference:
Sippel V, et al. Paper #AB0078. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology; June 10-13, 2015; Rome.
Disclosure: The researchers report no relevant financial disclosures.